13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001844645
Total reported value
$307.8M
$307.8M
10 檔
51.5%
According to the latest 13F quarterly dataset, Pivotal bioVenture Partners Investment Advisor LLC managed an equity portfolio of $307.8M at the end of Q3 2025, spanning 10 distinct U.S. exchange-listed positions.
Pivotal bioVenture Partners Investment Advisor LLC executed strategic sector rebalancing during Q3 2025, establishing 3 new positions while fully exiting 4 holdings and trimming 0 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PCVX | Vaxcyte Inc | Stock-Other | 28.58% | -1.59% | +5.16% | |
| 2 | OCS | Oculis Holding AG | Stock-Other | 23.38% | -9.18% | — | |
| 3 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 23.11% | -0.64% | — | |
| 4 | ZBIO | Zenas Biopharma Inc | Stock-Other | 10.00% | -0.09% | — | |
| 5 | TRVI | Trevi Therapeutics Inc | Stock-Other | 6.65% | +3.93% | +9.66% | |
| 6 | IMNM | Immunome Inc | Stock-Other | 3.40% | -0.69% | — | |
| 7 | BIOA | Bioage Labs Inc | Stock-Other | 2.22% | +1.12% | — | |
| 8 | RXRX | Recursion Pharmaceuticals-a | Stock-Healthcare | 1.68% | +0.06% | — | |
| 9 | ✓ | Rallybio CORP | Stock-Other | 0.69% | — | — | |
| 10 | BOLT | Bolt Biotherapeutics Inc | Stock-Other | 0.29% | -0.06% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PCVX | Vaxcyte Inc | +6.9% | +5.16% | Add |
| 2 | ZBIO | Zenas Biopharma Inc | +5.3% | — | Add |
| 3 | BIOA | Bioage Labs Inc | +0.2% | — | Unchanged |
| 4 | ✓ | Rallybio CORP | -0.6% | — | Unchanged |
| 5 | RXRX | Recursion Pharmaceuticals-a | -0.9% | — | Unchanged |
| 6 | ARQT | Arcutis Biotherapeutics Inc | -3.7% | — | Unchanged |
| 7 | OCS | Oculis Holding AG | -12.1% | — | Unchanged |
| 8 | TRVI | Trevi Therapeutics Inc | — | NEW | New buy |
| 9 | IMNM | Immunome Inc | — | NEW | New buy |
| 10 | ✓ | Inozyme Pharma Inc | — | EXIT | Sold out |
| 11 | VIGL | Vigil Neuroscience Inc | — | EXIT | Sold out |
| 12 | IOBTQ | Io Biotech Inc | — | EXIT | Sold out |
| 13 | BOLT1EUR | Bolt Biotherapeutics Inc | — | EXIT | Sold out |
| 14 | BOLT | Bolt Biotherapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Pivotal bioVenture Partners Investment Advisor LLC reported a total U.S. public equity portfolio value of $307.8M across 10 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including PCVX, OCS, ARQT) accounted for 51.5% of total reported equity market value during Q3 2025.
Top New Position Initiated
TRVI
市值: $11.5M
Top Position Liquidated / Trimmed
INOZYME PHARMA INC
前期市值: $4.1M
During Q3 2025, Pivotal bioVenture Partners Investment Advisor LLC's top holdings by market value included PCVX (28.6%)、OCS (23.4%)、ARQT (23.1%). The largest single position, PCVX, represented 28.6% of total portfolio value.
In Q3 2025, Pivotal bioVenture Partners Investment Advisor LLC made 9 total portfolio adjustments, initiating 3 new buys, adding to 2 positions, trimming 0 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.